Item 8.01 Other Events. On August 18, 2025, NeuroOne Medical Technologies Corporation announced that it has received U. S. Food and Drug Administration 510(k) clearance to market its OneRF®Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: August 18, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer